Back to Search
Start Over
Development of an Immunoassay for the Detection of Amyloid Beta 1-42 and Its Application in Urine Samples.
- Source :
- Journal of Immunology Research; 12/28/2020, p1-9, 9p, 2 Charts, 3 Graphs
- Publication Year :
- 2020
-
Abstract
- Amyloid beta peptides (Aβ1-42) have been found to be associated with the cause of Alzheimer's disease (AD) and dementia. Currently, methods for detecting Aβ1-42 are complicated and expensive. The present study is aimed at developing an indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) to detect Aβ1-42 by using a polyclonal antibody from alpaca, an application used in urine samples. The serum was collected from the alpaca after immunizing it with Aβ1-42 at 500 μg/injection 5 times. The ic-ELISA was developed and showed a half-maximal inhibitory concentration (IC50) of 103.20 ng/ml. The limit of detection (LOD) was 0.39 ng/100 μl. The cross-reactivity was tested with Aβ1-40 and 8 synthesized peptides that had sequence similarities to parts of Aβ1-42. The cross-reactivity of Aβ1-40 and peptide 1 (DAEFRHDSGYE) was 55% and 69.4%, respectively. The ic-ELISA was applied to analyze Aβ1-42 in the urine and precipitated protein urine samples. This method can be used for detecting a normal level of total soluble Aβ (approximately 1 ng in 5 mg of precipitated urine protein) and can be used for detecting the early stages of AD. It is considered to be an easy and inexpensive method for monitoring and diagnosing AD. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 23148861
- Database :
- Complementary Index
- Journal :
- Journal of Immunology Research
- Publication Type :
- Academic Journal
- Accession number :
- 147805050
- Full Text :
- https://doi.org/10.1155/2020/8821181